To Identify Urinary Biomarkers Associated With Gestational Diabetes Mellitus [GDM]

Last updated: September 30, 2023
Sponsor: Peking Union Medical College Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Diabetes And Hypertension

Diabetes (Pediatric)

Pregnancy Complications

Treatment

N/A

Clinical Study ID

NCT05992974
202303075GDM
K4087
  • Ages > 18
  • Female

Study Summary

Gestational diabetes mellitus(GDM) is one of the most common complications of pregnancy. The incidence of GDM is higher in Asian than in other regions, and GDM can increase the risk of a series of perinatal complications. The investigators has been committed to the early diagnosis of GDM, and several biomarkers in the first trimester and urinary proteomic markers that were associated with GDM have been found. Based on the previous work, the aim of this study was to verify the predictive ability of urinary proteomic markers for GDM that has been found in the previous study of the researchers. This study is a multi-center, prospective, and observational study. Urine samples will be collected twice, at 12 weeks and 24-28 weeks of gestation, respectively.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Women of childbearing age who are in early pregnancy(gestational age less than 12weeks);
  • Regular prenatal examination until delivery;
  • Older than 18 years old;
  • Obtained informed consent from participants and/or their family members.

Exclusion

Exclusion Criteria:

  • Twins or multiple pregnancy;
  • With impaired glucose tolerance or diabetes mellitus before pregnancy;
  • With severe chronic diseases or infectious diseases (e.g., liver disease, urinarysystem disease, cardiovascular disease, autoimmune disease, hematological disease,AIDS and other diseases before pregnancy);
  • Medications other than vitamins used during pregnancy;
  • Inability to understand and follow-up regularly;
  • Other conditions that were judged by the investigator to be ineligible forparticipation in the study.

Study Design

Total Participants: 1000
Study Start date:
August 31, 2023
Estimated Completion Date:
December 31, 2025

Study Description

The eligibility criteria are as follows:

  1. singleton pregnant women over 18 years old;

  2. gestational age less than 12 weeks;

  3. regular follow-up until delivery;

  4. able to understand and sign an informed consent.

The exclusion criteria of pregnant women are as follows:

  1. with impaired glucose tolerance or diabetes mellitus before pregnancy;

  2. severe chronic diseases or infectious diseases (e.g., liver disease, urinary system disease, cardiovascular disease, autoimmune disease, hematological disease, AIDS and other diseases before pregnancy);

  3. medications other than vitamins used during pregnancy;

  4. inability to understand and follow-up regularly;

  5. other conditions judged by the investigators to be inappropriate for participation in the study.

Connect with a study center

  • Mudanjiang First People's Hospital

    Mudanjiang, Heilongjiang
    China

    Active - Recruiting

  • Mudanjiang Maternal and Child Health Hospital

    Mudanjiang, Heilongjiang
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.